{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28matching%29&page=4", "query": { "intervention": "Placebo (matching)", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 6987, "total_pages": 699, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28matching%29&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28matching%29&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T23:02:51.596Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01934361", "title": "Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma Multiforme" ], "interventions": [ { "name": "buparlisib", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "lomustine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2014-02-28", "completion_date": "2016-07-07", "has_results": false, "last_update_posted_date": "2020-12-09", "last_synced_at": "2026-10-05T23:02:51.596Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Fayetteville, Arkansas • Chicago, Illinois + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01934361" }, { "nct_id": "NCT06388941", "title": "Iptacopan in Patients With ANCA Associated Vasculitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis" ], "interventions": [ { "name": "Iptacopan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2024-08-05", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-05T23:02:51.596Z", "location_count": 2, "location_summary": "Mesa, Arizona • Rochester, Minnesota", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06388941" }, { "nct_id": "NCT00244751", "title": "Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cirrhosis, Liver" ], "interventions": [ { "name": "GI262570 0.5 mg", "type": "DRUG" }, { "name": "GI262570 1.0 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "40 Years to 70 Years" }, "enrollment_count": 265, "start_date": "2005-11-02", "completion_date": "2008-03-13", "has_results": true, "last_update_posted_date": "2017-12-11", "last_synced_at": "2026-10-05T23:02:51.596Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00244751" }, { "nct_id": "NCT05176639", "title": "A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Thyroid Eye Disease" ], "interventions": [ { "name": "Veligrotug", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Viridian Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2022-11-16", "completion_date": "2025-03-27", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-05T23:02:51.596Z", "location_count": 29, "location_summary": "Aurora, California • Beverly Hills, California • Los Angeles, California + 22 more", "locations": [ { "city": "Aurora", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05176639" }, { "nct_id": "NCT04999839", "title": "Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Moderate to Severe Plaque Psoriasis" ], "interventions": [ { "name": "NDI-034858 study drug", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 259, "start_date": "2021-08-11", "completion_date": "2022-09-12", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-10-05T23:02:51.596Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bryant", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04999839" }, { "nct_id": "NCT04517396", "title": "FEnofibRate as a Metabolic INtervention for COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Fenofibrate/fenofibric acid", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Usual care", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 701, "start_date": "2020-08-18", "completion_date": "2022-03-30", "has_results": true, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-10-05T23:02:51.596Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04517396" }, { "nct_id": "NCT04173273", "title": "A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Etrasimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 379, "start_date": "2020-01-06", "completion_date": "2025-06-09", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-05T23:02:51.596Z", "location_count": 192, "location_summary": "Dothan, Alabama • Mobile, Alabama • Peoria, Arizona + 62 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04173273" }, { "nct_id": "NCT07201051", "title": "A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bronchiectasis" ], "interventions": [ { "name": "GSK3862995B", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 363, "start_date": "2025-10-30", "completion_date": "2027-12-10", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-05T23:02:51.596Z", "location_count": 31, "location_summary": "Mobile, Alabama • Phoenix, Arizona • La Palma, California + 27 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Palma", "state": "California" }, { "city": "Valencia", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07201051" }, { "nct_id": "NCT00814372", "title": "Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "MBX-102", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Actos", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 242, "start_date": "2008-12", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-05T23:02:51.596Z", "location_count": 5, "location_summary": "Burbank, California • Los Angeles, California • Las Vegas, Nevada + 2 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00814372" }, { "nct_id": "NCT01809327", "title": "A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canagliflozin 100 mg", "type": "DRUG" }, { "name": "Canagliflozin 300 mg", "type": "DRUG" }, { "name": "Metformin XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1186, "start_date": "2013-06-04", "completion_date": "2014-12-02", "has_results": true, "last_update_posted_date": "2017-07-11", "last_synced_at": "2026-10-05T23:02:51.596Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01809327" } ] }